[1] Panchapakesan U,Mather A,Pollock C.Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease[J].Clin Sci(Lond),2013,124(1):17-26. [2] Von Websky K.Reichetzeder C,Hocher B.Physiology and pathophysiology of incretins in the kidney[J].Curr Opin Nephrol Hypertens,2014,23(1):54-60. [3] 高远.内科疾病疗效评价标准[M].北京:人民卫生出版社,2002:118-119. [4] Nauck MA.Unraveling the science of incretion biology[J].Eur J inter Med,2009,Suppl 2:S303-S308.[5] Hattori S.Sitagliptin reduces albuminuria in patients with type 2 diabetes [J].Endocr J,2011,58(1):69-73. [6] Abd E,Motteleb DM,Elshazly SM.Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats:role of GLP-1 and GLP-1 receptor[J].Eur J Pharmacol,2013,720(1-3):158-165. [7] Ervinna N,Mita T,Yasunari E,et al.A DPP-4 inhibitor,suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice[J].Endocrinology,2013,154(3):1260-1270. [8] Kodera R,Shikata K,Kataoka HU,et al.Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes[J].Diabetologia,2011,54(4):965-978. [9] Fujita H,Morii T,Fujishima H,et al.The protective roles of GLP-1R signaling in diabetic nephropathy:possible mechanism and therapeutic potential[J].Kidney Int,2014,85(3):579-589. [10] Li W,Cui M,Wei Y.Inhibition of the expression of TGF-β1 and CTGF in human mesangial cells by exendin-4,a glucagonlikepeptide-1 receptor agonist [J].Cell Physiol Biochem,2012,30(3):749-757. [11] Alter ML,Ott IM,Von Websky,et al.DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy[J].Kidney Blood Press Res,2012,36(1):119-130. [12] Tanaka Y,Mori H,Okada Y,et al.Sitagliptin improves albuminuria in patients with type 2 diabetes[J].Diabetes Invest,2014,5(3):313-319.
2018, Vol. 35 
